By blocking key receptors involved in the T-cell-mediated immune response, such as programmed cell death protein-1 (PD-1), its ligand (PDL-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA4), an innate immune system-mediated tumor therapy is achieved. Here, PDCD1 is linked to neoplasm.